AUS
NZ
UK
CA
USA
IND
Highlights:
Pro Medicus Limited has experienced a remarkable share price increase of 97.13% in 2024, highlighting strong market performance.
The company reports impressive revenue and profit growth, with a compound annual growth rate (CAGR) of 33.4% in revenue and 39.0% in profit over the past three years.
Pro Medicus maintains a healthy financial position with a negative net debt of -$153 million and a return on equity (ROE) of 50.7%, indicating efficient capital utilization.
Pro Medicus Limited (ASX:PME) , founded in 1983, specializes in providing radiology IT software tailored for hospitals, imaging centers, and healthcare groups globally. The company's product suite includes radiology information systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualization solutions. A significant highlight of Pro Medicus's offerings is the Visage software, which empowers radiologists to remotely view large imaging files on mobile devices, facilitating timely diagnostic decisions and potentially enhancing patient outcomes.
Analyzing the company's financial performance reveals substantial growth metrics. Pro Medicus reported an annual revenue of AU$162 million, marking a compound annual growth rate (CAGR) of 33.4% over the past three years. This trend is critical, as revenue serves as the foundation for profitability.
The gross margin, a crucial indicator of product profitability, was reported at an impressive 99.8%. This figure reflects the efficiency of Pro Medicus's core offerings before accounting for overhead costs. Profit figures also demonstrate positive momentum, with the company reporting AU$83 million in profit last year, significantly up from AU$31 million three years prior, representing a CAGR of 39.0%.
Examining the company’s capital structure further underscores its financial health. Pro Medicus maintains a net debt of -AU$153 million, indicating a surplus of cash over debt obligations. Additionally, the debt-to-equity ratio stands at a mere 1.1%, suggesting prudent leverage. A notable return on equity (ROE) of 50.7% for FY24 reflects efficient utilization of shareholder equity, signifying that the company generates substantial value for its stakeholders.
Given the robust revenue growth, increasing profits, and strong return on equity, Pro Medicus Limited appears to be a company worth monitoring in 2025. Continued analysis of financial metrics and comparisons with industry peers will provide further insights into the company's performance and market valuation.
